14 sept. 2026•3 min de lecture
Takeda's Orexin Agonist Orzeyful Receives FDA Approval, Targets Narcolepsy and Beyond
Takeda secured FDA clearance for Orzeyful, the first orexin‑based therapy for type‑1 narcolepsy, and experts see potential expansion into arousal, cognition and fatigue treatments.